FDA clears Plavix for additional heart indication

09/10/2006 | United Press International

The FDA has cleared Bristol-Myers Squibb's and Sanofi's Plavix anti-clotting drug for reducing the risk of fatal heart attack and the risk of a recurrent heart attack, stroke or death in patients with acute STEMI. Patients who have survived a STEMI incident, the most severe form of heart attack, are at higher risk of another heart attack, stroke or death.

View Full Article in:

United Press International

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC